Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The effect of Baclofen administration on the evolution of the glial scar after spinal cord injury
FY 2023-24
Summary
Spinal cord injury (SCI) often results in a major loss of neurological functions that severely impact a person's quality of life. This loss of function is due to the migration of astrocytes to the lesion site to form a growth-inhibitory glial scar. Although astrocytes secrete growth-suppressing molecules, they have critical pro-regenerative effects after SCI that, if enhanced, are a promising method for restricting growth-inhibition post-injury. Astrocytes provide an anchor for axon growth and confine inflammatory neurodegenerative cells to the non-neural lesion core of the glial scar. There is currently no available drug that promotes regeneration after SCI. However, astrocytes are responsive to Baclofen, which we believe has the potential to promote regeneration after SCI by altering the formation of the glial scar. My MSc research aims to determine how Baclofen administration affects the development and composition of the glial scar using mice with a T12 dorsal column lesion as a model organism. To assess the development of the glial scar, mice will be euthanized at various time points, and their spinal cords will be stained with antibodies for quantitative immunofluorescence analyses of glial scar components. We hypothesize that migration of pro-regenerative astrocytes to the lesion site will increase, and the deposition of inflammatory cells will decrease in Baclofen-treated mice. There is an urgent need for an available drug to treat SCI. Baclofen has already been approved to treat SCI-associated spasticity, making it easily translated for clinical use to promote regeneration after SCI. Deciphering its possible regenerative effects is an important stepping stone in developing a regenerative treatment for SCI in the near future.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506289
Name
Seburn Eliana
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The effect of Baclofen administration on the evolution of the glial scar after spinal cord injury
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug; Glial Scar; Interactions; Regeneration; Spinal Cord Injury; Translational
Abstract
Spinal cord injury (SCI) often results in a major loss of neurological functions that severely impact a person's quality of life. This loss of function is due to the migration of astrocytes to the lesion site to form a growth-inhibitory glial scar. Although astrocytes secrete growth-suppressing molecules, they have critical pro-regenerative effects after SCI that, if enhanced, are a promising method for restricting growth-inhibition post-injury. Astrocytes provide an anchor for axon growth and confine inflammatory neurodegenerative cells to the non-neural lesion core of the glial scar. There is currently no available drug that promotes regeneration after SCI. However, astrocytes are responsive to Baclofen, which we believe has the potential to promote regeneration after SCI by altering the formation of the glial scar. My MSc research aims to determine how Baclofen administration affects the development and composition of the glial scar using mice with a T12 dorsal column lesion as a model organism. To assess the development of the glial scar, mice will be euthanized at various time points, and their spinal cords will be stained with antibodies for quantitative immunofluorescence analyses of glial scar components. We hypothesize that migration of pro-regenerative astrocytes to the lesion site will increase, and the deposition of inflammatory cells will decrease in Baclofen-treated mice. There is an urgent need for an available drug to treat SCI. Baclofen has already been approved to treat SCI-associated spasticity, making it easily translated for clinical use to promote regeneration after SCI. Deciphering its possible regenerative effects is an important stepping stone in developing a regenerative treatment for SCI in the near future.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Seburn, Eliana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~